Clinical Trials Logo

Plaque, Atherosclerotic clinical trials

View clinical trials related to Plaque, Atherosclerotic.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04267094 Terminated - Clinical trials for Atherosclerotic Plaque

Reduced Radiation Dose and IR-impact on Coronary Calcium Quantification

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

Evaluation of reduced radiation dose iterative reconstruction reconstructions for calcium scoring compared to full dose filtered back projection reconstructions

NCT ID: NCT02659150 Terminated - Clinical trials for Rheumatoid Arthritis

Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis

Start date: May 18, 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to test the hypothesis that anti-IL-6 therapy is effective for reducing plaque inflammation as measured by fluorine-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with rheumatoid arthritis (RA) who are synthetic disease-modifying antirheumatic drugs (dMARD) inadequate responders and are naive to biologic therapy.

NCT ID: NCT02105623 Terminated - Clinical trials for Coronary Arteriosclerosis

EARly Prevention of aTHeroma Progression

EARTH
Start date: June 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare standard therapy (risk factor control, life style modification) versus standard therapy plus low-dose rosuvastatin therapy (5mg/day) on progression of coronary atherosclerosis in statin naive individuals who have mild CAD (nonobstructive coronary atherosclerotic plaques) and normal LDL (low-density lipoprotein) cholesterol levels(〈130mg/dl).

NCT ID: NCT02009930 Terminated - Atherosclerosis Clinical Trials

Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service

Start date: November 5, 2013
Phase:
Study type: Observational

Hypothesis: Enlisted military members with 10 or more years of service and at least one cardiovascular risk factor will demonstrate a higher risk of future cardiac events as assessed by coronary artery calcium (CAC) scoring than the risk calculated by the Framingham Risk Score.

NCT ID: NCT01384747 Terminated - Clinical trials for Coronary Artery Disease

Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)

Start date: July 2011
Phase: Phase 4
Study type: Interventional

- Fimasartan will be more beneficial in stabilizing the plaque vulnerability compared to control group in deferred coronary lesions. - Fimasartan will be more beneficial in reducing total plaque volume compared to control group in deferred coronary lesions. - Fimasartan will be more beneficial in reducing functional impairment of stenotic lesions (assessed by FFR:Fractional Flow Reserve) in deferred coronary lesions.